Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

Direct-seller remains confident business will reach $8.5 bil. by 2007 with 20% operating margin, Exec VP-Asia Pacific, Europe, Middle East & Africa Robert Toth reports during Merrill Lynch Global Branded Consumer Products Conference Oct. 1. Exec says Avon will focus on Central and Eastern Europe as key areas to contribute to growth, highlights Russia as the biggest opportunity in the group. Firm recently announced plans to open $40 mil. manufacturing facility outside Moscow in mid-2004 (1"The Rose Sheet" Sept. 29, 2003, In Brief). Other nations Avon views as strategic regional opportunities include Turkey, Kazakhstan and Bosnia, Toth says...

You may also be interested in...



Avon

Direct-seller begins construction on $40 mil. manufacturing facility near Narofominsk, Russia to support firm's beauty business in the region. Russia is one of Avon's fastest growing markets, with sales expected to reach $500 mil. in 2007, firm says. The 250,000 square foot facility, expected to open in mid-2004, will employ over 800 workers and produce 185 mil. units of cosmetic products, Avon says. Items manufactured at the plant will be sold in Russia through Avon's 194,000 consultants, and in Ukraine and Kazakhstan. Avon has had a presence in Russia since 1995, with regional sales of $142 mil. in 2002...

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

RS011553

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel